Biostage, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 7.98 million compared to USD 4.87 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 0.55 a year ago.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | -14.18% | +2.22% | -53.91% |
1st Jan change | Capi. | |
---|---|---|
-53.91% | 38.36M | |
+12.50% | 229B | |
+14.52% | 195B | |
+17.51% | 142B | |
+28.96% | 109B | |
+3.27% | 64.85B | |
+18.16% | 54.33B | |
+7.63% | 52.09B | |
+10.95% | 45.15B | |
+5.10% | 37.39B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021